BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Airas L, Rissanen E, Rinne JO. Imaging neuroinflammation in multiple sclerosis using TSPO-PET. Clin Transl Imaging 2015;3:461-73. [PMID: 27331049 DOI: 10.1007/s40336-015-0147-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Owen DR, Narayan N, Wells L, Healy L, Smyth E, Rabiner EA, Galloway D, Williams JB, Lehr J, Mandhair H, Peferoen LA, Taylor PC, Amor S, Antel JP, Matthews PM, Moore CS. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. J Cereb Blood Flow Metab 2017;37:2679-90. [PMID: 28530125 DOI: 10.1177/0271678X17710182] [Cited by in Crossref: 85] [Cited by in F6Publishing: 52] [Article Influence: 17.0] [Reference Citation Analysis]
2 Singhal T, Rissanen E, Ficke J, Cicero S, Carter K, Weiner HL. Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET: A Clinically Feasible, Individualized Approach. Clin Nucl Med 2021;46:136-7. [PMID: 33208611 DOI: 10.1097/RLU.0000000000003398] [Reference Citation Analysis]
3 Magro-Checa C, Steup-Beekman GM, Huizinga TW, van Buchem MA, Ronen I. Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go? Front Med (Lausanne) 2018;5:340. [PMID: 30564579 DOI: 10.3389/fmed.2018.00340] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Barros C, Fernandes A. Linking Cognitive Impairment to Neuroinflammation in Multiple Sclerosis using neuroimaging tools. Mult Scler Relat Disord 2021;47:102622. [PMID: 33227630 DOI: 10.1016/j.msard.2020.102622] [Reference Citation Analysis]
5 Vainio SK, Dickens AM, Tuisku J, Eskola O, Solin O, Löyttyniemi E, Anthony DC, Rinne JO, Airas L, Haaparanta-Solin M. Cessation of anti-VLA-4 therapy in a focal rat model of multiple sclerosis causes an increase in neuroinflammation. EJNMMI Res 2019;9:38. [PMID: 31073768 DOI: 10.1186/s13550-019-0508-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Shen J, Yang B, Xie Z, Wu H, Zheng Z, Wang J, Wang P, Zhang P, Li W, Ye Z, Yu C. Cell-Type-Specific Gene Modules Related to the Regional Homogeneity of Spontaneous Brain Activity and Their Associations With Common Brain Disorders. Front Neurosci 2021;15:639527. [PMID: 33958982 DOI: 10.3389/fnins.2021.639527] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chaney AM, Johnson EM, Cropper HC, James ML. PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke. J Vis Exp 2018. [PMID: 29985311 DOI: 10.3791/57243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Wang Z, Mascarenhas C, Jia X. Positron Emission Tomography After Ischemic Brain Injury: Current Challenges and Future Developments. Transl Stroke Res 2020;11:628-42. [PMID: 31939060 DOI: 10.1007/s12975-019-00765-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Gunn RN, Rabiner EA. Imaging in Central Nervous System Drug Discovery. Semin Nucl Med 2017;47:89-98. [PMID: 27987561 DOI: 10.1053/j.semnuclmed.2016.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen Z, Haider A, Chen J, Xiao Z, Gobbi L, Honer M, Grether U, Arnold SE, Josephson L, Liang SH. The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO. J Med Chem 2021;64:17656-89. [PMID: 34905377 DOI: 10.1021/acs.jmedchem.1c01571] [Reference Citation Analysis]
11 Brusaferri L, Alshelh Z, Martins D, Kim M, Weerasekera A, Housman H, Morrissey EJ, Knight PC, Castro-Blanco KA, Albrecht DS, Tseng CE, Zürcher NR, Ratai EM, Akeju O, Makary MM, Catana C, Mercaldo ND, Hadjikhani N, Veronese M, Turkheimer F, Rosen BR, Hooker JM, Loggia ML. The pandemic brain: Neuroinflammation in non-infected individuals during the COVID-19 pandemic. Brain Behav Immun 2022;102:89-97. [PMID: 35181440 DOI: 10.1016/j.bbi.2022.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Deussing M, Blume T, Vomacka L, Mahler C, Focke C, Todica A, Unterrainer M, Albert NL, Lindner S, von Ungern-sternberg B, Baumann K, Zwergal A, Bartenstein P, Herms J, Rominger A, Brendel M. Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [18F]GE180 PET quantification. NeuroImage 2018;165:83-91. [DOI: 10.1016/j.neuroimage.2017.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
13 Goud NS, Bhattacharya A, Joshi RK, Nagaraj C, Bharath RD, Kumar P. Carbon-11: Radiochemistry and Target-Based PET Molecular Imaging Applications in Oncology, Cardiology, and Neurology. J Med Chem 2021;64:1223-59. [PMID: 33499603 DOI: 10.1021/acs.jmedchem.0c01053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sen MK, Almuslehi MSM, Shortland PJ, Mahns DA, Coorssen JR. Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers. Int J Mol Sci 2021;22:7377. [PMID: 34298997 DOI: 10.3390/ijms22147377] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Sucksdorff M, Tuisku J, Matilainen M, Vuorimaa A, Smith S, Keitilä J, Rokka J, Parkkola R, Nylund M, Rinne J, Rissanen E, Airas L. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol Neuroimmunol Neuroinflamm 2019;6:e574. [PMID: 31355310 DOI: 10.1212/NXI.0000000000000574] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
16 Millett CE, Burdick KE, Kubicki MR. The Effects of Peripheral Inflammation on the Brain-A Neuroimaging Perspective. Harv Rev Psychiatry 2022;30:54-8. [PMID: 34995035 DOI: 10.1097/HRP.0000000000000323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Albrecht DS, Granziera C, Hooker JM, Loggia ML. In Vivo Imaging of Human Neuroinflammation. ACS Chem Neurosci 2016;7:470-83. [PMID: 26985861 DOI: 10.1021/acschemneuro.6b00056] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 20.5] [Reference Citation Analysis]
18 Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, Rinne J, Airas L. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis. J Nucl Med 2017;58:1646-51. [PMID: 28336784 DOI: 10.2967/jnumed.116.183020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
19 Vuorimaa A, Rissanen E, Airas L. In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease. Contrast Media Mol Imaging 2017;2017:6975841. [PMID: 29348737 DOI: 10.1155/2017/6975841] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
20 Atabati H, Yazdanpanah E, Mortazavi H, Bajestani SG, Raoofi A, Esmaeili SA, Khaledi A, Saburi E, Afshari JT, Sathyapalan T, Moghaddam AS, Sahebkar A. Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis. Adv Exp Med Biol 2021;1286:87-105. [PMID: 33725347 DOI: 10.1007/978-3-030-55035-6_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tang D, Fujinaga M, Hatori A, Zhang Y, Yamasaki T, Xie L, Mori W, Kumata K, Liu J, Manning HC, Huang G, Zhang MR. Evaluation of the novel TSPO radiotracer 2-(7-butyl-2-(4-(2-([18F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide in a preclinical model of neuroinflammation. Eur J Med Chem 2018;150:1-8. [PMID: 29505933 DOI: 10.1016/j.ejmech.2018.02.076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
22 Bunai T, Terada T, Kono S, Yokokura M, Yoshikawa E, Futatsubashi M, Miyajima H, Ouchi Y. Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study. J Neurol Sci 2018;385:30-3. [PMID: 29406909 DOI: 10.1016/j.jns.2017.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
23 Vāvere AL, Scott PJH. Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. Semin Nucl Med 2017;47:429-53. [PMID: 28826519 DOI: 10.1053/j.semnuclmed.2017.05.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
24 O'Loughlin E, Madore C, Lassmann H, Butovsky O. Microglial Phenotypes and Functions in Multiple Sclerosis. Cold Spring Harb Perspect Med 2018;8:a028993. [PMID: 29419406 DOI: 10.1101/cshperspect.a028993] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
25 Ricigliano VAG, Morena E, Colombi A, Tonietto M, Hamzaoui M, Poirion E, Bottlaender M, Gervais P, Louapre C, Bodini B, Stankoff B. Choroid Plexus Enlargement in Inflammatory Multiple Sclerosis: 3.0-T MRI and Translocator Protein PET Evaluation. Radiology 2021;:204426. [PMID: 34254858 DOI: 10.1148/radiol.2021204426] [Reference Citation Analysis]
26 Beaino W, Janssen B, Kooij G, van der Pol SMA, van Het Hof B, van Horssen J, Windhorst AD, de Vries HE. Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis. J Neuroinflammation 2017;14:259. [PMID: 29273052 DOI: 10.1186/s12974-017-1034-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
27 Airas L, Rissanen E, Rinne J. Imaging of microglial activation in MS using PET: Research use and potential future clinical application. Mult Scler 2017;23:496-504. [PMID: 27760860 DOI: 10.1177/1352458516674568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
28 Mahapatra S, Reis Marques T. Antipsychotics, versatility in action. Proc Natl Acad Sci U S A 2021;118:e2108946118. [PMID: 34244436 DOI: 10.1073/pnas.2108946118] [Reference Citation Analysis]
29 Stys PK, Tsutsui S. Recent advances in understanding multiple sclerosis. F1000Res 2019;8:F1000 Faculty Rev-2100. [PMID: 31885862 DOI: 10.12688/f1000research.20906.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]